The goal of this clinical research study is to find the highest tolerable dose of the
combinations of pazopanib and either lapatinib or trastuzumab that can be given to patients
with advanced cancer. The safety of the drug combinations will also be studied.
Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for
tumor growth. This may prevent or slow the growth of cancer cells.
Lapatinib is designed to prevent or slow down the growth of cancer cells by blocking 2
proteins on the surface of the cancer cell, which are HER 1 and HER 2 receptors.
Trastuzumab is designed to prevent or slow down the growth of cancer cells by blocking
proteins inside the cancer cell, called the Her2/neu receptor.